Exelixis Announces Preliminary Fourth Quarter and Full Year 2022 Financial Results, Provides 2023 Financial Guidance, and Outlines Key Priorities and Milestones for 2023Business Wire • 01/08/23
Exelixis to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023 — Presentation to be webcast on www.exelixis.com —Business Wire • 01/03/23
Exelixis Announces Initiation of the STELLAR-304 Phase 3 Pivotal Trial Evaluating Zanzalintinib in Patients with Advanced Non-Clear Cell Kidney CancerBusiness Wire • 12/22/22
2 Biotech Stocks to Buy Hand Over Fist in 2023 and 1 to Avoid Like the PlagueThe Motley Fool • 12/16/22
Nasdaq Bear Market: 5 Exceptionally Cheap Growth Stocks You'll Regret Not Buying on the DipThe Motley Fool • 12/10/22
Exelixis Provides Update on Phase 3 CONTACT-01 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Metastatic Non-Small Cell Lung Cancer Previously Treated with Immunotherapy and ChemotherapyBusiness Wire • 12/08/22
Exelixis Announces Initial Dose-Escalation Results from the First-in-Human Phase 1 Trial Evaluating XL102 in Patients with Advanced Solid Tumors at SABCS 2022Business Wire • 12/08/22
Exelixis to Present at the Virtual JMP Securities Hematology and Oncology Summit on December 7, 2022Business Wire • 11/30/22
Exelixis and Catalent Enter into New License Agreement for Three Antibody-Drug Conjugate Programs with the Potential to Accelerate Exelixis' Biologics PipelineBusiness Wire • 11/03/22
Exelixis and Sairopa Establish Exclusive Clinical Development Collaboration and Option Agreement to Develop ADU-1805, a Potentially Best-in-Class Monoclonal Antibody Targeting SIRPαBusiness Wire • 11/01/22